ABATACEPT
(Orencia)Standard Prescription
Abatacept __ mg IV (__ mg/kg/dose) {frequency}.
Infuse over 30 minutes.
or
Abatacept __ mg SC {frequency}
Dosages
Juvenile Idiopathic Arthritis:
Intravenous
< 75 kg: 10 mg/kg/dose IV Q2wks x 3 doses, then Q4wks thereafter
75 to 100 kg: 750 mg/dose IV Q2wks x 3 doses, then Q4wks thereafter
> 100 kg: 1000 mg/dose IV Q2wks x 3 doses, then Q4wks thereafter
Subcutaneous
>2 yrs:
10 to <25 kg: 50 mg SC once weekly
25 to <50 kg: 87.5 mg SC once weekly
>50 kg: 125 mg SC once weekly
Intravenous
< 75 kg: 10 mg/kg/dose IV Q2wks x 3 doses, then Q4wks thereafter
75 to 100 kg: 750 mg/dose IV Q2wks x 3 doses, then Q4wks thereafter
> 100 kg: 1000 mg/dose IV Q2wks x 3 doses, then Q4wks thereafter
Subcutaneous
>2 yrs:
10 to <25 kg: 50 mg SC once weekly
25 to <50 kg: 87.5 mg SC once weekly
>50 kg: 125 mg SC once weekly
Mechanism of Action
Modified antibody that decreases the activation of T-cells
Forms Supplied
Intravenous Injection: 250mg vial
Comments
Infusion reactions are uncommon (<4%) and generally mild. If infusion reaction occurs, stop or slow infusion, administer acetaminophen, diphenhydramine or corticosteroid.
Most common adverse effects include dizziness, nausea, vomiting, headache, hypersensitivity and rhinitis.
Patients who develop serious reactions during the infusion (eg. bronchospasm, wheezing, hypotension) should not receive the drug again.
Risk of infection: do not use in patients with active infection. All patients should be evaluated for both active and latent tuberculosis before starting treatment.
Administration of live vaccinations to patients on abatacept not recommended.
References
316, 317, 318, 319
US Food & Drug Administration. New Pediatric Labeling Information Database - Detail (Trade name: Orencia) [Internet]. Maryland: US Food & Drug Administration; 2017 [Dec 2020]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125118s2111b1.pdf.
Last Edited
2021-06-23 04:23:02